{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-25-045896","form_type":"8-K","ticker":"EWTX","cik":"0001710072","company_name":"Edgewise Therapeutics, Inc.","filed_at":"2025-05-08T23:59:59+00:00","discovered_at":"2026-05-14T18:02:49.422082+00:00","generated_at":"2026-05-22T04:54:19.423185+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"Edgewise Q1 net loss $40.8M; positive Phase 2 HCM data and $188M offering highlighted","bullets":["Positive top-line data from Phase 2 CIRRUS-HCM: EDG-7500 reduced LVOT-G without meaningful LVEF changes; improved KCCQ and NT-proBNP.","Raised $188M net in April 2025 public offering; pro-forma cash exceeds $624M as of close.","Q1 2025 net loss of $40.8M ($0.43 loss/share); R&D expense $36.8M, G&A stable at $9.2M.","Sevasemten Phase 2 LYNX/FOX Duchenne data expected Q2 2025; Part D CIRRUS-HCM data due H2 2025."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-25-045896","json":"https://secwatch.observer/filing/0001104659-25-045896.json","markdown":"https://secwatch.observer/filing/0001104659-25-045896.md","text":"https://secwatch.observer/filing/0001104659-25-045896.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1710072/000110465925045896/0001104659-25-045896-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1710072/000110465925045896/tm2513845d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-22T04:54:19.423185+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}